KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Acquisitions & Divestments (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Acquisitions & Divestments for 13 consecutive years, with $273.4 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments rose 225.54% to $273.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $722.2 million through Dec 2025, up 82.58% year-over-year, with the annual reading at $722.2 million for FY2025, 82.58% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $273.4 million at Halozyme Therapeutics, up from $209.6 million in the prior quarter.
  • The five-year high for Change in Acquisitions & Divestments was $590.0 million in Q2 2022, with the low at $15.6 million in Q4 2023.
  • Average Change in Acquisitions & Divestments over 5 years is $122.3 million, with a median of $76.9 million recorded in 2021.
  • The sharpest move saw Change in Acquisitions & Divestments soared 667.59% in 2022, then crashed 90.95% in 2023.
  • Over 5 years, Change in Acquisitions & Divestments stood at $69.8 million in 2021, then tumbled by 71.18% to $20.1 million in 2022, then dropped by 22.52% to $15.6 million in 2023, then skyrocketed by 438.34% to $84.0 million in 2024, then skyrocketed by 225.54% to $273.4 million in 2025.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $273.4 million, $209.6 million, and $189.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.